MX367707B - Compounds for use in prevention and treatment of neurodegenerative diseases and pain. - Google Patents
Compounds for use in prevention and treatment of neurodegenerative diseases and pain.Info
- Publication number
- MX367707B MX367707B MX2016005174A MX2016005174A MX367707B MX 367707 B MX367707 B MX 367707B MX 2016005174 A MX2016005174 A MX 2016005174A MX 2016005174 A MX2016005174 A MX 2016005174A MX 367707 B MX367707 B MX 367707B
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine
- methyl
- pain
- prevention
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 3
- 229960005305 adenosine Drugs 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- DFETZYGISAXEEJ-FMZWZIECSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(2-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1SC=CC1CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N DFETZYGISAXEEJ-FMZWZIECSA-N 0.000 abstract 1
- OPUWCBGREITRRH-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-bromothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound BrC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N OPUWCBGREITRRH-HIDXMTOYSA-N 0.000 abstract 1
- NYXVWLZCIYPJGF-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC=1C(=CSC1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N NYXVWLZCIYPJGF-HIDXMTOYSA-N 0.000 abstract 1
- MPRPJVVMNCYFGX-HPDNKFCTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-chlorothiophen-3-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N MPRPJVVMNCYFGX-HPDNKFCTSA-N 0.000 abstract 1
- PMSLJWQPNPWCRD-IEVJCCNJSA-N ClC=1SC=CC1CNC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1.BrC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N Chemical compound ClC=1SC=CC1CNC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1.BrC1=CC(=CS1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N PMSLJWQPNPWCRD-IEVJCCNJSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N 6 -[(3-halothien-2-yl)methyl]adenosine, N 6 -[(4-halothien-2-yl)methyl]adenosine, and N 6 -[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N 6 -[(2-bromothien-3-yl)methyl]adenosine, N 6 -[(4-bromothien-3-yl)methyl]adenosine, N 6 -[(5-bromothien-3-yl)methyl]adenosine N 6 -[(2-chlorothien-3-yl)methyl]adenosine, N 6 -[(4-chlorothien-3-yl)methyl]adenosine, and N 6 -[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005174A MX2016005174A (en) | 2016-08-11 |
| MX367707B true MX367707B (en) | 2019-09-03 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005174A MX367707B (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (en) |
| EP (1) | EP3060566B1 (en) |
| JP (1) | JP6534997B2 (en) |
| KR (1) | KR102313314B1 (en) |
| CN (1) | CN106414456B (en) |
| AU (1) | AU2014340114B2 (en) |
| BR (1) | BR112016008901B1 (en) |
| CA (1) | CA2927699C (en) |
| IL (1) | IL245103B (en) |
| MX (1) | MX367707B (en) |
| RU (1) | RU2695358C2 (en) |
| SG (1) | SG11201603063WA (en) |
| WO (1) | WO2015061426A1 (en) |
| ZA (1) | ZA201603118B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180030461A (en) | 2015-05-29 | 2018-03-23 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | Nucleoside preparations for reducing harmful effects of genes including extended nucleotide repeats |
| EP3573996B1 (en) * | 2017-01-27 | 2022-06-15 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| TWI901931B (en) * | 2022-02-10 | 2025-10-21 | 中央研究院 | Method of treating spinal cord injury and composition for use therein |
| WO2024010910A1 (en) * | 2022-07-07 | 2024-01-11 | Academia Sinica | Method of treating schizophrenia and composition for use therein |
| CN120548177A (en) * | 2022-12-29 | 2025-08-26 | 周美吟 | Methods of treating sleep disorders and compositions for use therein |
| KR20250165367A (en) * | 2023-03-17 | 2025-11-25 | 아카데미아 시니카 | Method for treating tuberous sclerosis or epilepsy and composition for use therein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8274187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| ES2095960T3 (en) * | 1990-09-25 | 1997-03-01 | Rhone Poulenc Rorer Int | COMPOUNDS THAT HAVE ANTI-HYPERTENSIVE AND ANTI-ISCHEMICAL PROPERTIES. |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| UY27939A1 (en) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
| ES2645043T3 (en) * | 2009-11-13 | 2017-12-01 | Academia Sinica | Double-acting compounds that target the A2A adenosine receptor and adenosine transporter for the prevention and treatment of neurodegenerative diseases |
| EP2511283A4 (en) | 2009-12-10 | 2013-07-03 | Inst Materia Medica Cams | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES, AND USES THEREOF |
| HK1204534A1 (en) * | 2012-02-09 | 2015-11-27 | 布兰德泵浦有限责任公司 | Decorative detectable warning panel having improved grip |
| CN104363757B (en) * | 2012-02-11 | 2017-05-24 | 中央研究院 | Methods and compositions for treating pain |
-
2014
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/en active
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/en active Active
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/en active Active
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/en active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/en active IP Right Grant
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/en active IP Right Grant
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016118282A (en) | 2017-11-28 |
| EP3060566A1 (en) | 2016-08-31 |
| CA2927699C (en) | 2022-07-05 |
| US10301348B2 (en) | 2019-05-28 |
| BR112016008901A2 (en) | 2020-05-12 |
| RU2016118282A3 (en) | 2018-06-18 |
| AU2014340114B2 (en) | 2018-10-18 |
| JP6534997B2 (en) | 2019-06-26 |
| WO2015061426A1 (en) | 2015-04-30 |
| EP3060566B1 (en) | 2018-09-05 |
| EP3060566A4 (en) | 2017-06-14 |
| JP2016535019A (en) | 2016-11-10 |
| CA2927699A1 (en) | 2015-04-30 |
| CN106414456B (en) | 2018-12-14 |
| KR20160086852A (en) | 2016-07-20 |
| IL245103B (en) | 2019-02-28 |
| KR102313314B1 (en) | 2021-10-19 |
| SG11201603063WA (en) | 2016-05-30 |
| US20160264613A1 (en) | 2016-09-15 |
| IL245103A0 (en) | 2016-06-30 |
| ZA201603118B (en) | 2019-04-24 |
| NZ719740A (en) | 2021-02-26 |
| BR112016008901B1 (en) | 2022-08-23 |
| MX2016005174A (en) | 2016-08-11 |
| RU2695358C2 (en) | 2019-07-23 |
| CN106414456A (en) | 2017-02-15 |
| AU2014340114A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200192A1 (en) | TIGIT . antibodies | |
| IL264049A (en) | Compounds, compositions, and methods for the treatment of disease | |
| CY1120862T1 (en) | INDICATORS OF INDEPENDENCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | |
| IL264156A (en) | Compounds, compositions, and methods for the treatment of disease | |
| PH12016501107A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| PH12015501648A1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| MX375752B (en) | BRUTON'S TYROSINE KINASE INHIBITORS. | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| MX369623B (en) | Fused bicyclic compounds for the treatment of disease. | |
| MX367707B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain. | |
| EP3046582A4 (en) | Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases | |
| MX382092B (en) | Heterocyclic compounds for the treatment of disease | |
| HK1254231A1 (en) | Mito-honokiol compounds and methods of synthesis and use thereof | |
| MX370897B (en) | Fused bicyclic compounds for the treatment of disease | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity | |
| IN2013MU03118A (en) | ||
| MX2016002930A (en) | Liver x receptor (lxr) modulators. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |